Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy

Haematologica

Volumn 91, Issue 2, 2006, Pages 244-247

  Burighel, Nicoletta ^a   Ghezzi, Silvia ^b   Nozza, Silvia ^b   Del Bianco, Paola ^c   Lazzarin, Adriano ^b,d   Tambussi, Giuseppe ^b   Poli, Guido ^b,d   De Rossi, Anita ^a,e  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e AIDS Reference Center   (Italy)

Author keywords

ART; EBV; HIV 1; IL 2

Indexed keywords

INTERLEUKIN 2; VIRUS DNA;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; VIREMIA;

ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HIV-1; HUMANS; INTERLEUKIN-2; VIRAL LOAD;

EID: 33644532551     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996;335:1350-6.
2. Tambussi G, Gezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, et al. Efficacy of low dose intermittent subcutaneous interleukin (IL)-2 in antiviral drug-experienced human immunodeficiency virus-infected person with detectable virus load: a controlled study of three IL-2 regimens with antiviral drug therapy. J Infect Dis 2001;183:1476-84.
3. Jacobson LE, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996;93:10405-10.
4. Malnati M, Broccolo F, Nozza S, Sarnati L, Ghezzi S, Locatelli G, et al. Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. Blood 2002;100:1575-8.
5. Ometto L, Menin C, Masiero S, Bonaldi L, Del Mistro A, Cattelan AM, et al. Molecular profile of Epstein-Barr virus in immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997;90:313-22.
6. Gaidano G, Carbone A, Dalla Favera R. Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity. Am J Pathol 1998;152:623-30.
7. Kerl JH, Miller A, Fauci AS. Effect of tumor necrosis factor α on mitogen-activated human B cells. J Exp Med 1987;166:786-91.
8. Macchia D, Almerigogna F, Parronchi P, Ravina A, Maggi E, Romagnani S. Membrane tumor necrosis factor α is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 1993;363:464-6.
9. Mauray S, Fuzzati-Armentero MT, Trouillet P, Ruegg M, Nicoloso G, Hart M, et al. Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. Eur J Immunol 2000;30:2065-73.
10. David D, Bani L, Moreau JL, Treilhou MO, Nakara T, Joussemet M, et al. Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Natl Acad Sci USA 1998;95:11348-53.
11. Righetti E, Ballon G, Ometto L, Menin C, Zanchetta M, Chieco-Bianchi L, et al. Dynamics of Epstein Barr virus in HIV-1 infected subjects on highly active antiretroviral therapy. AIDS 2002;16:63-73.
12. Nakanishi K, Hirose S, Yoshimoto T, Ishizashi H, Hiroishi K, Tanaka T, et al. Role and regulation of interleukin (IL)-2 receptor α and β chains in IL-2 driven B-cell proliferation. Proc Natl Acad Sci USA 1992;89:3551-5.
13. Patke CL, Shearer WT. gp120 and TNF-α-induced modulation of human B cell function: proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression. J Allergy Clin Immunol 2000;105:975-82.
14. Fortis C, Soldini L, Ghezzi S, Colombo S, Tambussi G, Vicenzi E, et al. Tumor necrosis factor alfa, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2. AIDS Res Hum Retrov 2002;18:491-9.
15. Becknell B, Caligiuri MA. Interleukin-2, interleukin 15, and their role in human natural killer cells. Adv Immunol 2005;86:209-39.
16. Baiocchi RA, Caligiuri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1994;91:5577-81.